Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia.
This study was designed to see whether the high vs low serum level of imipramine influenced the outcome of in vivo exposure therapy on patients with agoraphobia. Thirty-six subjects completed the Hopkins Symptom Checklist-90 one week before treatment and weekly throughout treatment. Both groups demonstrated equal improvement. It was noted that the rate of improvement differed for different symptom subscales: (1) Hostility, Paranoia and Psychotic symptom ratings improved over the first three weeks of treatment, (2) Interpersonal Sensitivity, Anxiety and Depression ratings improved throughout the first seven weeks of treatment and (3) Phobic Anxiety, Somatization and Obsessive Compulsure symptom ratings continued to improve throughout the entire 12 week course of treatment. Responsive vs nonresponsive subjects could be significantly differentiated after one week of treatment on the basis of their responses to the Psychoticism subscale.
Cox
D J
DJ
Department of Behavioral Medicine and Psychiatry, University of Virginia Medical School, Charlottesville 22901.
Ballenger
J C
JC
Laraia
M
M
Hobbs
W R
WR
Peterson
G A
GA
Hucek
A
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000379:Agoraphobia / Q000523:psychology / Q000628:therapy*; D001521:Behavior Therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007099:Imipramine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010698:Phobic Disorders / Q000628:therapy*
D007099:Imipramine